Yahoo
NSE - Delayed Quote INR

Gland Pharma Limited (GLAND.NS)

2,891.20 -33.20 (-1.14%)
At close: 3:30:03 PM GMT+5:30
GLAND.NS Q1 2027 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for GLAND.NS
  • Previous Close 2,924.40
  • Open 2,924.00
  • Bid --
  • Ask --
  • Day's Range 2,860.00 - 2,949.90
  • 52 Week Range 1,573.60 - 2,988.40
  • Volume 732,462
  • Avg. Volume 870,196
  • Market Cap (intraday) 476.952B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 42.25
  • EPS (TTM) 68.43
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield 20.00 (0.77%)
  • Ex-Dividend Date Aug 10, 2026
  • 1y Target Est 2,771.71

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

www.glandpharma.com

4,332

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 8/12/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

GLAND.NS
69.17%
S&P BSE SENSEX (^BSESN)
8.51%

1-Year Return

GLAND.NS
52.07%
S&P BSE SENSEX (^BSESN)
2.83%

3-Year Return

GLAND.NS
80.25%
S&P BSE SENSEX (^BSESN)
19.36%

5-Year Return

GLAND.NS
31.18%
S&P BSE SENSEX (^BSESN)
42.16%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 17.43B
Earnings 3.67B

Q3

FY26

Q4

FY26

0
5B
10B
15B

Analyst Insights

View More

Analyst Price Targets

1,940.00 Low
2,771.71 Average
2,891.20 Current
3,350.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    482.43B

  • Enterprise Value

    451.67B

  • Trailing P/E

    42.83

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.87

  • Price/Book (mrq)

    4.25

  • Enterprise Value/Revenue

    6.39

  • Enterprise Value/EBITDA

    21.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.97%

  • Return on Assets (ttm)

    6.27%

  • Return on Equity (ttm)

    10.53%

  • Revenue (ttm)

    64.31B

  • Net Income Avi to Common (ttm)

    10.27B

  • Diluted EPS (ttm)

    68.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    33.59B

  • Total Debt/Equity (mrq)

    2.74%

  • Levered Free Cash Flow (ttm)

    4.23B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: